SCHEMBL4101413

SCHEMBL4101413

CN(c1cccc(Cl)c1)S(=O)(=O)Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.46
PFKFB3 Q16875 3/20 0.41
GLP1R P43220 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 2/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 2/20 0.35
ALOX15 P16050 1/20 0.35
SCN1A P35498 2/20 0.35
SCN5A Q14524 2/20 0.35
SCN8A Q9UQD0 2/20 0.35
NAE1 Q13564 1/20 0.34
UBA3 Q8TBC4 1/20 0.34
NSD2 O96028 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4100057 0.91 FADS1 (0.41) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL4105895 0.87 PFKFB3 (0.37) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL3412817 0.86 SMN1; SMN2 (0.42) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL3401353 0.86 PFKFB3 (0.41) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL4106792 0.85 HPGDS (0.43) PFKFB3GLP1RSMN1; SMN2KDM4ETSHR
SCHEMBL4097398 0.84 KDM4E (0.38) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL4117077 0.83 FADS1 (0.38) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL4104986 0.82 LMNA (0.39) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL4097503 0.80 MET (0.39) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E
SCHEMBL3403995 0.80 FADS1 (0.55) FADS1PFKFB3GLP1RSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B FADS1 2801/4885PFKFB3 3870/4885GLP1R 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.